Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gastrografin for Small Bowel Obstruction in Children
NCT03573921Phase 3Terminated
- Start
- Sep 2019
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of diatrizoate meglumine + diatrizoate sodium in small bowel obstruction (SBO) (2 arms). Primary endpoint: Rate of surgical intervention at 6 months. Started Sep 2019; status: terminated.
02
Drugs
diatrizoate meglumine + diatrizoate sodium
03
Conditions
small bowel obstruction (SBO)
Beyond the preview
Go deeper on NCT03573921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03573921.